Moore's law 2015 that the pace of advancement has slowed, starting at the 22 nm feature width around 2012, and continuing at 14 nm. Brian Krzanich, the former CEO of Intel, announced, "Our cadence today is closer to two and a half years than two." Intel is expected to reach the 10 nm node in 2018, a three-year cadence. Intel also stated in 2017 that hyperscaling would be able to continue the trend of Moore's law and offset the increased cadence by aggressively scaling beyond the typical doubling of transistors. Krzanich cited Moore's 1975 revision as a precedent for the current deceleration,
SmithKline Corp. v. Eli Lilly & Co. Kefzol and SK's Ancef—identical to one another—were cheaper, partial substitutes for patented Keflin, which had a higher sales price and generated more profit but was cheaper to manufacture than the other two. Keflin accounted for most of Lilly's cephalosporin sales. Kefzol/Ancef, however, was cutting into Keflin sales as hospitals partially substituted cheaper, and in some ways better, Kefzol/Ancef for Keflin. Nalebuff explains: The bundling program "was effective at keeping SmithKline out of the market while also preserving Keflin's monopoly," because: SmithKline Corp. v. Eli Lilly & Co. SmithKline Corp. v. Eli Lilly and Co., 575 F.2d 1056 (3d Cir. 1978),